A Novel External Auditory Canal Squamous Cell Carcinoma Cell Line Sensitive to CDK4/6 Inhibition

Author: García-Marín, R., Cabal, V.N., Fernández-Cedrón Bermejo, C., Riobello, C., Suárez-Fernández, L., Codina-Martínez, H., Navarro-García, A., Lorenzo-Guerra, S.L., García-Martínez, J., Vivanco, B. and López, F.

American Academy of Otolaryngology-Head and Neck Surgery Foundation, 2022


The authors of this study aimed to characterize CAE606 cells derived from a squamous cell carcinoma (SCC) of the external auditory canal (EAC) and to demonstrate the suitability of this cell model for testing candidate therapeutic agents. The CytoSMART Omni was used to evaluate CAE606 cell migration in a standard wound-healing assay following treatment with cell cycle inhibitor, palbociclib. All in all, this study demonstrates the value of CAE606 cell line in investigating new therapeutics targeting cell cycle control pathways.